Product Name Atosiban Acetate;
Cas No. 90779-69-4;
Sequence Mpa-D-Tyr(ET)-Ile-Thr-Asn-Cys-Pro-Orn-Gly-NH2(Cyclic1-6);
Molecular Formula C43H67N11O12S2;
Molar Mass 994.199 g/mol;
Purity ≥98%;
Impurity ≤0.5% ;
Storage Temperature 2-8℃;
Packing Size 1G/Bottle, 10G/Bottle,50G/Bottle or at customers reqirement.
Atosiban Acetate can postpone its imminent premature birth.
Mechanism of action: Atosiban is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra). Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua.
Originator Company: Ferring Pharmaceuticals
Dosage for formulation: 7.5mg/ml
Generic API process in our company: Atosiban Acetate is one of our main peptide projects, related documents will be submitted to the international FDA.
Cas No. 90779-69-4;
Sequence Mpa-D-Tyr(ET)-Ile-Thr-Asn-Cys-Pro-Orn-Gly-NH2(Cyclic1-6);
Molecular Formula C43H67N11O12S2;
Molar Mass 994.199 g/mol;
Purity ≥98%;
Impurity ≤0.5% ;
Storage Temperature 2-8℃;
Packing Size 1G/Bottle, 10G/Bottle,50G/Bottle or at customers reqirement.
Atosiban Acetate can postpone its imminent premature birth.
Mechanism of action: Atosiban is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra). Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua.
Originator Company: Ferring Pharmaceuticals
Dosage for formulation: 7.5mg/ml
Generic API process in our company: Atosiban Acetate is one of our main peptide projects, related documents will be submitted to the international FDA.